CHCWM – Cancer & Hematology Centers of West Michigan

Debio 0123-102 (Debiopharm)

Debio 0123-102 (Debiopharm)

Description:  A Phase 1, Dose Finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors, followed by an Expansion Part to Assess Safety and Preliminary Anti-Tumor Activity

Mechanism of Action: WEE1 inhibitor (suppresses the G2-M checkpoint in the cell cycle)

Target Patient Population:  All solid tumors in Dose Escalation

Study Design:  Drug is given orally daily.